Program
Bupropion
Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.
Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.
Drug pageBupropion: every studyMany companies study it; this page follows only the 19 they lead. All 217 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 80 open or running | phase 3since Sep 24, 2002 | Sep 24, 2002 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Rose Research Centerits history only | 20 open or running | phase 3since May 11, 2020 | May 11, 2020 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Apr 16, 2009 | Apr 16, 2009 | none ahead |
| Takedaits history only | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2002First study: phase 3 study in Seasonal Affective DisorderFirst studyNCT00046241 · 300 enrolled · United States, Canada
- Oct 30, 2002Phase 3 study in Attention Deficit Disorder with HyperactivityNCT00048360 · 162 enrolled · United States
- Jan 7, 20032 phase 3 studies in Depressive Disorder, MajorNCT00051272, NCT00051259
- Sep 25, 2003Phase 1 study in Depressive DisorderNCT00069459 · 250 enrolled · United States
- Oct 5, 2004Phase 3 study in Depressive Disorder, MajorNCT00093288 · 364 enrolled · Australia, Belgium, Finland and more
- Aug 24, 2005Phase 2 study in Depressive DisorderNCT00135512 · 234 enrolled · Japan
- Jul 14, 2014Phase 3 study in Depressive Disorder, MajorNCT02191397 · 534 enrolled · China
TargetBeta
“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
All 8 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02191397Depressive Disorder, Major · China | 3 | Completed | Oct 10, 2016 | 534 |
| NCT00135512Depressive Disorder · Japan | 2 | Completed | May 28, 2007 | 234 |
| NCT00093288Depressive Disorder, Major · Australia, Belgium, Finland and more | 3 | Completed | Oct 2005 | 364 |
| NCT00069459Depressive Disorder · United States | 1 | Completed | Jun 3, 2004 | 250 |
| NCT00051272Depressive Disorder, Major · United States | 3 | Completed | Jun 2004 | 425 |
| NCT00051259Depressive Disorder, Major · United States | 3 | Completed | Jun 2004 | 420 |
| NCT00048360Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Jun 2003 | 162 |
| NCT00046241Seasonal Affective Disorder · United States, Canada | 3 | Completed | Jun 2003 | 300 |
How it is read
Names in the registry
- “Bupropion”, 7 entries
- “bupropion hydrochloride”, 3 entries
- “Extended-release Bupropion Hydrochloride”, 2 entries
- “Extended-release bupropion hydrochloride”, 2 entries
- “Bupropion HCl”, 2 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 5 studies
- Depressive Disorder, Major, 4 studies
- Depressive Disorder, 2 studies
- Seasonal Affective Disorder, 2 studies
- Obesity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.